TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10610011
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension with food
Study: 10610011
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension 1500 mg/day
Study: 1725026
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of ramipril daily
Study: 1725026
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of ramipril in combination with 20 mg of furosemide daily
Study: 6390537
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of multiple chemotherapy and radiotherapy for patients with positive laparotomy or unfavorable prognostic indicators
Study: 31215538
Drug: Standard conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conservative treatment (control group, n=50)
Study: 29898066
Drug: EndoVac (EV)
Normalized name: Summer's Eve Medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: EndoVac (EV) + 2% Chlorhexidine gel + saline solution (CHXg + SS)
Study: 29898066
Drug: EndoVac (EV)
Normalized name: Summer's Eve Medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: EndoVac (EV) + 2% Chlorhexidine solution (CHXs)
Study: 29898066
Drug: EndoVac (EV)
Normalized name: Summer's Eve Medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: EndoVac (EV) + Saline solution (SS)
Study: 29898066
Drug: Conventional irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional irrigation (CI) + 2% Chlorhexidine gel + saline solution (CHXg + SS)
Study: 29898066
Drug: Conventional irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional irrigation (CI) + 2% Chlorhexidine solution (CHXs)
Study: 29898066
Drug: Conventional irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional irrigation (CI) + Saline solution (SS)
Study: 24290979
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment for opioid dependence
Study: 24290979
Drug: Neonates requiring
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonates requiring pharmacotherapy for NAS
Study: 24290979
Drug: Neonates not
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonates not requiring pharmacotherapy for NAS
Study: 18084949
Drug: Epidermal growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal growth factor receptor monoclonal antibodies (EGFR‐MoABs)
Study: 18084949
Drug: Anti‐angiogenic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐angiogenic drugs
Study: 10634923
Drug: Nutritional counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counseling with fortified drink supplements (group B)
Study: 7972617
Drug: Naloxone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (5 mg i.v.)
Study: 45539
Drug: Penbutolol 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 25 mg
Study: 31448846
Drug: Lofexidine (LFX)
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lofexidine (LFX) 2.4 mg/day
Study: 23949882
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/week, with dose escalation until serum total testosterone of 20 nmol/l)
Study: 12800099
Drug: rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4 mg/d) for 12 weeks
Study: 8781766
Drug: Troglitazone (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (200, 400, 600, or 800 mg once daily, or 200 or 400 mg twice daily)
Study: 8781766
Drug: Troglitazone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (600 and 800 mg/day)
Study: 8781766
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 and 600 mg doses)
Study: 8781766
Drug: Troglitazone (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (highest doses)
Study: 3884746
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of cyclophosphamide (CTX), Adriamycin (ADR), and DDP (CAD)
Study: 29231524
Drug: Need-in-row therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Need-in-row therapy
Study: 24863090
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise training program (60 minutes of aerobic and stretching exercises, twice a week for 12 weeks)
Study: 18407904
Drug: Protein powder
Normalized name: Pre-Protein Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein powder supplement aiming at 36 g of protein per day
Study: 18407904
Drug: Energy and
Normalized name: Energy And Endurance Testosterone UP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy and protein supplements aiming at 37.6 g of protein and 500 kcal per day
Study: 10071426
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: 240 mg CBS every 12 h for 6 weeks
Study: 10071426
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: 240 mg CBS every 12 h for 6 weeks, plus metronidazole 500 mg every 8 h plus tetracycline 500 mg every 8 h for 10 days
Study: 10071426
Drug: Group III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: 240 mg CBS every 12 h for 6 weeks, plus metronidazole 500 mg every 8 h plus amoxicillin 750 mg every 12 h for 10 days
Study: 28111410
Drug: Tolvaptan treatment
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan treatment for 15 days or longer (15DL)
Study: 28111410
Drug: Tolvaptan treatment
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan treatment for 14 days or shorter (14DS)
Study: 24197826
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (NS) 5 ml injected into the epidural space before catheter insertion
Study: 22067058
Drug: Immediate 2-weeks
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immediate 2-weeks treatment group (N=28)
Study: 17923489
Drug: GSK364735 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK364735 (50 to 400 mg single doses, 100 to 600 mg repeated doses for 8 days)
Study: 8179044
Drug: Audio self‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audio self‐administered questionnaire
Study: 8179044
Drug: Written self‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written self‐administered questionnaire
Study: 23544125
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/d plus Ezetimibe 10 mg/d
Study: 14615636
Drug: Corticosteroids (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (standard treatment)
Study: 14615636
Drug: Adjunctive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive agents (new treatments)
Study: 10636509
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) therapy
Study: 26811529
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Oxaliplatin and FU + LV)
Study: 15321815
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Fe and 10 mg Zn (Fe+Zn group)
Study: 9843082
Drug: Ultrahigh-dose methylcobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrahigh-dose methylcobalamin (25 mg/day, intramuscularly, for 14 days)
Study: 9843082
Drug: Low-dose methylcobalamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methylcobalamin (0.5 mg/day, intramuscularly, for 14 days)
Study: 22515
Drug: Pipothiazine palmitate
Normalized name: Pipothiazine palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipothiazine palmitate (100 mg, injected every 4th week)
Study: 22515
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate (25 or 37.5 mg, injected every 3rd week)
Study: 31136834
Drug: Guideline-based care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based care (GBC) + referral to Psychologically Informed Physical Therapy (PIPT)
Study: 23497371
Drug: Extended anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended anticoagulation treatment (continuing warfarin treatment for a further 2 years)
Study: 23497371
Drug: Routine anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine anticoagulation treatment (discontinuing warfarin treatment after 3-6 months)
Study: 15717477
Drug: Oral polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polio vaccine (OPV) first dose
Study: 15717477
Drug: Oral polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polio vaccine (OPV) second dose
Study: 11911558
Drug: Tramadol/acetaminophen (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/acetaminophen (37.5 mg/325 mg) tablets QID for 10 days
Study: 10414461
Drug: Neuronal autoantibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuronal autoantibody titers during chemotherapy
Study: 7672496
Drug: GLP-1 [7-36
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 [7-36 amide] (all doses) after glucose stimulation
Study: 7672496
Drug: GLP-1 [7-36
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 [7-36 amide] (all doses)
Study: 1983712
Drug: Niperotidine (460
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niperotidine (460 mg administered at 22.00)
Study: 23924233
Drug: Fluticasone Furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone Furoate (FF) 100 μg
Study: 23924233
Drug: Fluticasone Furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone Furoate and Vilanterol (FF/VI) 100/25 μg
Study: 18257343
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Chinese patent medicine
Study: 15312215
Drug: N-acetyl-L-cystein (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-L-cystein (NAC) infusion (150 mg/kg bolus followed by 12.5 mg/kg/hour for 6 hours)
Study: 15312215
Drug: Dextrose (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose (5% solution) administered at the same dosage as NAC
Study: 9542480
Drug: Avitriptan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avitriptan (150 mg doses, 2 hours apart)
Study: 7992348
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg mebendazole (Janssen)
Study: 7992348
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg mebendazole (Pharmamed)
Study: 2730505
Drug: guided mastery
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: guided mastery treatment based on self‐efficacy theory
Study: 2730505
Drug: stimulus exposure
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: stimulus exposure treatment
Study: 2730505
Drug: delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: delayed treatment
Study: 26246322
Drug: Total Protein
Normalized name: Total Protein Reagent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Protein Intake (TPro) ≥1.0 to <1.2 g · kg(‐1) · d(‐1)
Study: 26246322
Drug: Total Protein
Normalized name: Total Protein Reagent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Protein Intake (TPro) ≥1.2 g · kg(‐1) · d(‐1)
Study: 26246322
Drug: Total Protein
Normalized name: Total Protein Reagent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Protein Intake (TPro) <1.0 g · kg(‐1) · d(‐1)
Study: 20390281
Drug: Mud‐bath therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud‐bath therapy with mineral water from the Sillene Spring at Chianciano Spa
Study: 11765592
Drug: Cetirizine hydrochloride
Normalized name: Cetirizine Hydrochloride
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine hydrochloride 5 mg and pseudoephedrine hydrochloride 120 mg (CTZ/PSE)
Study: 7870932
Drug: Cocaine and
Normalized name: Cocaine and morphine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine and ethanol administration
Study: 20721962
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of activated carbon nanoparticles
Study: 20721962
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of methylene blue
Study: 12660266
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg testosterone implant plus daily oral placebo
Study: 12660266
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg testosterone plus oral Q 75 microg/day
Study: 12660266
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg testosterone plus oral Q 75 microg/day
Study: 11766652
Drug: Alternative therapies
Normalized name: HERBS/ALTERNATIVE THERAPIES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative therapies such as conservative treatment and plating
Study: 7877826
Drug: 131I-HIPDM injection
Normalized name: iobenguane (131I)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 131I-HIPDM injection
Study: 19113926
Drug: Daily teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily teriparatide for 15 months
Study: 9279891
Drug: Radiolabelled pessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiolabelled pessary formulation
Study: 9279891
Drug: Replens (polycarbophil)
Normalized name: Aspergillus repens
DrugBank: Aspergillus repens (DB10449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replens (polycarbophil) gel
Study: 23702236
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CPAP and speech therapy
Study: 23702236
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham speech therapy)
Study: 16420253
Drug: Trizivir (TZV)
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Trizivir (TZV) twice daily (n = 85)
Study: 16420253
Drug: Combivir/nelfinavir (COM/NFV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combivir/nelfinavir (COM/NFV) 1250 mg twice daily (n = 88)
Study: 16420253
Drug: Stavudine/lamivudine/nelfinavir (d4T/3TC/NFV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine/lamivudine/nelfinavir (d4T/3TC/NFV) 40 mg+150 mg+1250 mg twice daily (n = 81)
Study: 12562722
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg nightly for 7 days before IOS dose
Study: 12562722
Drug: Itraconazole oral
Normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution (IOS) 400 mg
Study: 11059872
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy for 12 months
Study: 11059872
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy for 6 months
Study: 8473720
Drug: moclobemide 200
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide 200 mg
Study: 8473720
Drug: moclobemide 400
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide 400 mg
Study: 27508319
Drug: fat-modified diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fat-modified diet plus cholestyramine (8 g twice daily)
Study: 24797765
Drug: Additional educational
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional educational material (SAGA tool) in treatment-naïve patients
Study: 24797765
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment in treatment-naïve patients
Study: 18265446
Drug: New platelet
Normalized name: Platelet Lysate
DrugBank: Platelet Lysate (DB15869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New platelet products using platelet additive solutions
Study: 14759085
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus 100 mg/day ASA (group A, n = 70)
Study: 14759085
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day ASA alone (group B, n = 70)
Study: 9338539
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate powder (250 microg twice daily)
Study: 9338539
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aerosol (200 microg four times daily)
Study: 8081133
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of early amniotomy and early oxytocin
Study: 30953543
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (1.5 g), thiamine (100 mg), and hydrocortisone (50 mg) every 6 hours until 16 administrations or ICU discharge.
Study: 27829367
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg IN ketamine
Study: 27829367
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg IM morphine
Study: 22314136
Drug: Measles vaccine
Normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccine at 4 months of age
Study: 22314136
Drug: Measles vaccine
Normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccine at 9 months of age (group 1)
Study: 15940126
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 50 microg LPS
Study: 15940126
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone 20 mg/d for 6 days
Study: 11752998
Drug: Intrathecal adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal adenosine (0.25-2.0 mg)
Study: 2390255
Drug: Thiopental sodium
Normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental sodium by infusion throughout CPB (n = 52)
Study: 2390255
Drug: Thiopental sodium
Normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental sodium 15 mg/kg by bolus before aortic declamping (n = 48)
Study: 6115596
Drug: Morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine + Placebo
Study: 6115596
Drug: Morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine + Cimetidine (H2)
Study: 6115596
Drug: Morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine + Diphenhydramine (H1)
Study: 6115596
Drug: Morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine + Cimetidine (H2) + Diphenhydramine (H1)
Study: 28216232
Drug: BIIB074 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB074 150 mg three times per day for 21 days, followed by random assignment to BIIB074 or placebo for up to 28 days.
Study: 25552403
Drug: 850 mg
Normalized name: bran 850 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 850 mg metformin hydrochloride administered p.o. in the evening of day 4 and in the morning of day 5
Study: 25552403
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trimethoprim administered p.o. twice daily for 5 days
Study: 23967069
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (school-delivered sexuality programming)
Study: 679592
Drug: Phase I
Normalized name: Nuvelle TS Phase I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I drug testing program
Study: 8889673
Drug: Intranasal heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal heroin (6 mg)
Study: 8889673
Drug: Intranasal heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal heroin (12 mg)
Study: 8889673
Drug: Intramuscular heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular heroin (6 mg)
Study: 8889673
Drug: Detection times
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection times for total morphine by GC‐MS and immunoassay (300‐ng/mL cutoff concentration)
Study: 1988535
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with morphine sulfate (MS) alone
Study: 1988535
Drug: PCA plus
Normalized name: PCA Plus 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA plus continuous infusion of morphine sulfate (PCA + CI)
Study: 29891957
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy and behaviour change counselling
Study: 26823037
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basic therapies only)